SFJ Pharmaceuticals

SFJ Pharmaceuticals

Based: Pleasanton, CA
Raised: $35 million
Investor: Clarus Ventures

The scoop: Back in January SFJ announced a deal to collaborate with Pfizer on a late-stage study of axitinib for Asian markets. The renal cell carcinoma pact exemplifies what the company is all about. It partners with pharma and biotech on drugs that need special handling to break into Japanese and other emerging Asian markets. SFJ finances the late-stage registration study and then takes a cut of the royalties on an approval. And it has had some substantial backing from Clarus as well as Abingworth and Fintech.

SFJ Pharmaceuticals

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.